Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis - Trial NCT06391645
Access comprehensive clinical trial information for NCT06391645 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Beijing Tiantan Hospital and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Tiantan Hospital
Timeline & Enrollment
Phase 2/3
May 01, 2024
Dec 01, 2026
Primary Outcome
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Summary
Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases,
 with most patients dying from respiratory failure 3-5 years after the onset. The purpose of
 this study is to explore the efficacy and safety of nerve growth factor (NGF) encapsulated
 with 2-methacryloyloxyethyl phosphorylcholine (MPC) nanocapsules in the treatment of ALS
 patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06391645
Non-Device Trial